PEPTIDE GUIDE

What Is Retatrutide?

Retatrutide is an investigational peptide medicine, which means it is still being tested and has not been approved. Its active molecule is a chain of amino acids. It is designed to activate three receptors, which are receiving points on cells, for the GIP, GLP-1 and glucagon hormone signals. These signals affect appetite, blood sugar, digestion and how the body uses energy. Activating all three is why retatrutide is called a triple agonist.

Clinical trials in people have reported substantial average reductions in body weight and blood sugar. Clinical trials progress through stages called phases. Phase 2 asks whether a treatment appears to work, explores the levels used in the research and records common side effects. Phase 3 uses larger groups to confirm benefits and collect more safety information before a possible application for approval. Eli Lilly and Company, the pharmaceutical company developing retatrutide, has now published several Phase 3 trials in peer-reviewed journals, where independent experts examine the work before publication. Other results remain company announcements. Publication strengthens the public evidence base but does not establish regulatory approval.

Research statusInvestigational medicine with completed Phase 3 trials
Development codeLY3437943
Peptide typeGIP, GLP-1 and glucagon triple agonist
Trial stagePhase 3 clinical trials
Last reviewed17 November 2026
THE SHORT ANSWER

Retatrutide is a once-weekly investigational peptide that activates the receptors for three hormone signals: GIP, GLP-1 and glucagon. Phase 2 and several Phase 3 trials have been published in peer-reviewed journals. Further Phase 3 findings remain company announcements. The findings are promising, but some Phase 3 details have not yet been published in full, approval has not been granted, and researchers are still establishing the long-term balance between benefits and risks.

What kind of molecule is retatrutide?

Retatrutide is a synthetic peptide, meaning that it is made in a laboratory. It was developed from the sequence of GIP, an incretin hormone that the gut releases after food and that helps the body respond to a meal. Its amino-acid sequence has been changed so that it can activate three related receptors and remain active for much longer than the natural hormones.

The molecule also includes a fatty-acid side chain. This helps it bind to albumin, a common protein in the blood, and slows how quickly the body removes it. Its longer activity allowed researchers to give it once a week in clinical trials.

Researchers first identified the molecule as LY3437943 during development. Retatrutide is the public scientific name used in the research programme, rather than a brand name. It has no approved retail brand name.

Calling it a peptide is accurate, but that description alone says little about what it does. Peptides are chains of amino acids. Their effects depend on their structure and the receptors they activate.

Why is it called a triple agonist?

An agonist is a molecule that activates a receptor and starts a response in the cell. Retatrutide activates three:

ReceptorNatural signal associated with itWhy researchers are interested
GIP receptorGlucose-dependent insulinotropic polypeptideHelping release insulin after food and influencing how the body handles nutrients and fat tissue
GLP-1 receptorGlucagon-like peptide-1Helping release insulin when blood sugar is high, reducing appetite and slowing digestion
Glucagon receptorGlucagonHelping the liver release stored energy and affecting how much energy the body uses, while also having the potential to raise blood sugar

Semaglutide activates GLP-1 receptors. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity to those two signals.

The word “triple” can sound as though the molecule simply combines three separate medicines. It does not. The three signals interact, and retatrutide has its own balance of activity at each receptor. Researchers therefore have to study its effects in people rather than predict them by counting receptors.

How might retatrutide work?

The GLP-1 and GIP parts of retatrutide can support the release of insulin, the hormone that helps move sugar from the blood into cells, when blood sugar is high. GLP-1 activity can also reduce glucagon in some circumstances, slow digestion and increase fullness. These effects can lower food intake and improve blood-sugar control.

Glucagon has a different role. It is a hormone that helps the liver release stored sugar into the blood. Activity at its receptor may also increase the amount of energy the body uses and promote the use of stored energy. Researchers designed retatrutide to combine these possible effects with the blood-sugar-lowering actions of GIP and GLP-1.

This balancing act is central to the molecule. Too much glucagon activity could work against glucose control. Too little might add little to the effects already available from GIP and GLP-1 activity. The useful balance has to be demonstrated in people rather than assumed from theory.

An early human study found that retatrutide delayed gastric emptying, which means it slowed how quickly food left the stomach after a meal. That may contribute to fullness and changes in blood sugar after eating, although it is only one part of the medicine's overall effect.

What did Health Canada's November 2026 peptide contamination warning find?

On 12 November 2026, Health Canada reported that laboratory testing had identified *Sphingomonas aquatilis/melonis* bacteria in an injectable peptide product seized from a retailer in Ottawa. The retailer's unauthorised inventory included products labelled retatrutide. The agency did not say that every product on its inventory list, or every batch of the named compound, tested positive for bacteria.

This is a product-quality and safety finding, not a new clinical trial of the peptide. Bacterial contamination in material intended for injection can cause serious infection, including sepsis. The agency also warned that a label saying 'for research use only' does not demonstrate sterility or make an unauthorised product suitable for human use. The finding cannot be used to estimate contamination rates across the wider market or to judge the quality of material used in controlled clinical studies.

Is retatrutide approved?

No. Retatrutide remains investigational in the United States as of 2 November 2026.

In its September 2026 update, Eli Lilly and Company said it planned a US approval submission in the first quarter of 2027. This is the company's timetable, not an FDA approval date. Regulators would still need to examine the evidence, manufacturing controls and proposed labelling before deciding whether the benefits outweigh the risks.

There is therefore no retatrutide vial, pen, tablet or powder approved by the US Food and Drug Administration (FDA). A product sold online under the name retatrutide is not made equivalent to the clinical-trial medicine by using the same name.

This matters for more than legality. Clinical trials use material that has been identified and tested, made under controlled conditions, given according to a set study plan and monitored by medical teams. A product labelled for research may contain a different substance or amount, unwanted contaminants or bacteria, or may not remain stable as expected.

What did the Phase 2 obesity trial find?

The Phase 2 obesity trial was published in a medical journal after independent expert review. It included 338 adults with obesity, or overweight plus at least one weight-related condition. Participants did not have type 2 diabetes. Chance decided whether each person received one of several retatrutide study levels or a placebo, an inactive comparison treatment, for 48 weeks.

Administration levels studied

The amounts in the trial were measured in milligrams (mg). They are included here to describe the research accurately, not to guide personal use.

Trial assignmentHow it was given in the studyWhy the group was included
Retatrutide 1 mgOnce weeklyTo study a lower level
Retatrutide 4 mgOnce weekly, with different starting approachesTo compare the effects of different levels
Retatrutide 8 mgOnce weekly, with different starting approachesTo compare the effects of different levels
Retatrutide 12 mgOnce weekly, increased according to the study planTo study the highest planned level
PlaceboOnce weeklyTo provide an inactive comparison group

These are documented research levels, not personal dosing information. Researchers increased some participants' study levels in planned steps and provided clinical supervision.

At 48 weeks, average body-weight change ranged from about 8.7% at 1 mg to 24.2% at 12 mg, compared with 2.1% in the placebo group. In the 12 mg group, 63% of participants reached at least 20% weight loss and 26% reached at least 30%.

Average weight was still falling in some higher-level groups at week 48. The study was not long enough to show when the average would stop falling or what would happen over several years.

The trial was relatively small for judging safety. It could identify common side effects, but could not rule out rare problems or harms that take a long time to appear.

What did the Phase 2 diabetes trial find?

A separate Phase 2 trial studied 281 adults with type 2 diabetes for 36 weeks. Participants received retatrutide, placebo or dulaglutide. Dulaglutide is an approved type 2 diabetes medicine that activates the GLP-1 receptor. It gave the researchers an active medicine to compare with retatrutide, rather than relying only on an inactive placebo.

At week 24, the higher retatrutide groups produced larger average reductions in HbA1c than placebo. HbA1c is a blood test that reflects a person's average blood-sugar level over roughly the previous three months. At week 36, average weight changes in the higher groups reached about 16.9%, compared with about 3.0% for placebo and 2.0% for dulaglutide.

The trial showed that, within this molecule and study plan, activity at the glucagon receptor did not prevent an overall reduction in blood sugar. It did not show whether retatrutide prevents heart, circulation or kidney problems over the long term. It also did not compare retatrutide with the administration levels now used in studies and approved products containing semaglutide or tirzepatide.

What has Phase 3 shown so far?

As of 2 November 2026, the programme includes peer-reviewed publications and sponsor announcements. An announcement gives selected results before a full paper is available; a published trial provides a more detailed account that other researchers can scrutinise. Neither is a marketing authorisation.

TRIUMPH-1: obesity without diabetes

TRIUMPH-1 randomly assigned 2,339 adults without diabetes to retatrutide or an inactive placebo for 80 weeks. Double blinding meant that participants and study teams did not know the assignment during treatment. In the publication's treatment-regimen analysis, average weight changes were −17.6%, −23.7% and −25.0% in the 4, 9 and 12 mg trial assignments, respectively, versus −3.9% with placebo. These are research assignments, not personal dosing instructions.

The trial also included groups with knee osteoarthritis, a condition involving joint damage and pain, and obstructive sleep apnoea. These were planned studies within the larger trial. Pain and breathing findings apply to those groups, rather than all 2,339 participants. Gastrointestinal adverse events were most common.

TRIUMPH-2: obesity with type 2 diabetes

The published TRIUMPH-2 trial included 1,152 adults followed for 80 weeks. Its treatment-regimen analysis reported average weight changes of −11.9%, −16.8% and −18.8% in the 4, 9 and 12 mg trial assignments, respectively, versus −5.1% with placebo. Earlier announcements used an efficacy analysis and gave larger reductions. Each percentage needs its analysis attached.

Diarrhoea occurred in 27–34% of retatrutide participants versus 13% with placebo; nausea in 14–28% versus 8%. Hypotension, meaning low blood pressure, and dysaesthesia, meaning abnormal or unpleasant skin sensation, were more frequent with retatrutide. Permanent discontinuation because of adverse events or death occurred in 4%, 12% and 8% of the retatrutide groups versus 5% with placebo. Investigators judged the seven deaths across all groups unrelated to treatment. That judgement does not make the study large enough to rule out rare harm.

What did the separate sleep-apnoea publication add?

The October 2026 report analysed 243 participants without diabetes and 448 with type 2 diabetes. Both groups had obstructive sleep apnoea, in which the upper airway repeatedly narrows or closes during sleep. The apnoea–hypopnoea index, or AHI, counts complete or partial breathing interruptions per hour.

At 80 weeks, the higher retatrutide groups had larger AHI reductions than placebo in both populations. Under the report's hybrid analysis, the additional reductions compared with placebo were about 22–24 events per hour without diabetes and 14–15 with diabetes. A hybrid analysis uses different assumptions for different events occurring after randomisation, such as treatment failure. The paper also reported intention-to-treat analyses.

These findings concern breathing severity during the trial. They do not establish a cure, a retatrutide approval or instructions to stop existing sleep-apnoea treatment.

TRANSCEND-T2D-1: diabetes without other glucose-lowering medicines

This 40-week placebo-controlled trial is also published, rather than available only as an announcement. It enrolled 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise. HbA1c fell by 1.69–1.94 percentage points across retatrutide groups versus 0.81 with placebo. Weight changes were −11.5% to −15.3% versus −2.6%, using the treatment-regimen analysis.

Adverse-event discontinuations occurred in 2–5% with retatrutide versus none with placebo. No severe hypoglycaemia, meaning dangerously low blood glucose, was reported. The findings apply to this relatively early-diabetes population and do not establish long-term prevention of complications.

Which results remain company announcements?

TRIUMPH-3 studied people with established cardiovascular disease, and TRIUMPH-4 studied people with knee osteoarthritis. The sources linked here are sponsor announcements rather than full journal papers. Weight reduction or pain improvement does not establish fewer heart attacks, strokes or cardiovascular deaths.

TRANSCEND-T2D-2 now provides a direct comparison with semaglutide, discussed below. Its October 2026 results remain a sponsor announcement.

How should the Phase 3 figures be read?

Three points prevent the headline numbers from becoming misleading.

First, they are group averages. Individual results vary, and some participants stop because of side effects or other reasons.

Second, the group studied matters. Average weight change in people without diabetes should not be treated as the expected result in people with diabetes, heart or circulation disease, or another condition.

Third, an estimand defines the treatment effect a trial aims to estimate. A treatment-regimen analysis includes the consequences of stopping or interrupting treatment under its specified methods. An efficacy analysis can estimate a hypothetical result if treatment continued. Check the paper's definitions before comparing percentages. Peer review is also different from independent replication: a sponsor-funded published study remains sponsor-funded.

The findings still matter. These are large trials in which chance decided who entered each treatment group, helping to make the groups reasonably comparable at the start. Their current publication status also needs to be described accurately.

Is retatrutide better than semaglutide or tirzepatide?

There is now a direct semaglutide comparison, but its scope needs care. On 28 October 2026, Lilly announced TRANSCEND-T2D-2 results in adults with type 2 diabetes. At 80 weeks, its efficacy analysis reported HbA1c reductions of 2.2 percentage points in both retatrutide groups versus 1.8 with Ozempic 2 mg. Average weight changes were −19.5% and −20.9% versus −9.4%.

Adverse-event discontinuations were 4.8% and 7.9% versus 2.7%. Dysaesthesia was reported in 4.8% and 6.5% versus 2.7%; digestive events were common in all groups. These are topline sponsor findings pending a full paper.

The comparator was Ozempic in diabetes, not every semaglutide formulation or obesity regimen. TRIUMPH-5 is a separate comparison with tirzepatide. It would therefore be premature to declare retatrutide universally superior to either medicine. Clinical benefit includes tolerability, serious outcomes and durability as well as weight and blood-glucose changes.

What side effects have trials reported?

The September TRIUMPH-2 sponsor report gives a more detailed breakdown of common events. The figures below are percentages of participants in each study assignment, not probabilities that can be transferred to an unapproved product or a different population.

EventRetatrutide 4 mgRetatrutide 9 mgRetatrutide 12 mgPlacebo
Diarrhoea27.4%33.5%33.6%13.2%
Nausea13.7%20.8%28.0%8.0%
Constipation14.0%16.2%16.8%9.4%
Reduced appetite5.8%12.3%17.1%4.5%
Vomiting5.5%10.2%15.7%4.2%
Dysaesthesia4.5%5.6%7.3%0.7%
Stopping because of adverse events3.8%11.6%7.7%4.9%

The discontinuation row concerns adverse events. The rounded figures in the published trial account above use its combined category of adverse events or death, so their definitions should not be silently interchanged. The sponsor also reported HbA1c reductions up to 1.6 percentage points. Improvements in blood pressure, blood lipids or blood glucose do not by themselves prove fewer cardiovascular events.

Digestive side effects have been the most common. Across studies and company announcements these have included:

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Reduced appetite

They have generally been described as mild or moderate and were more frequent while the study level was being increased. “Generally” does not mean harmless. Digestive symptoms can become severe, contribute to dehydration or lead someone to leave a trial.

The Phase 2 obesity study also found that heart rate increased more at higher study levels. The increase reached its highest point during the study and later declined. Some participants developed an arrhythmia, which is an abnormal heart rhythm, or changes in skin sensation. Larger and longer studies are needed to understand these findings and whether they cause important health problems.

Published Phase 3 studies confirm that digestive problems remain prominent. The trial-specific figures above also show why discontinuation, blood-pressure changes and altered skin sensation deserve attention. An adverse event occurs during a study but is not necessarily caused by treatment. Regulators must assess the complete evidence before any approved warning list can be established.

What serious risks remain under study?

Retatrutide does not yet have an approved prescribing label, so it would be wrong to copy the finished warning list from semaglutide or tirzepatide and present it as though regulators had assigned it to retatrutide.

Researchers and regulators will still examine risks related to the hormone signals retatrutide affects and the problems seen in trials. These include inflammation or other problems involving the pancreas, gallbladder problems, severe digestive illness, kidney injury linked to dehydration, low blood sugar when combined with other blood-sugar-lowering medicines, changes in heart rate and possible worsening of diabetic eye disease when blood sugar improves quickly.

Longer studies are especially important for assessing rare problems and whether treatment changes the risk of heart, circulation or kidney events. A study designed specifically to examine heart and kidney outcomes is publicly listed.

Findings in animals, concerns linked with similar medicines and observations in people are different kinds of evidence. If retatrutide is approved, its label will state who should not use it, which serious risks need prominent warnings and what checks may be needed during treatment.

What do we know about weight regain after stopping?

Long-term evidence about what happens after people stop retatrutide remains limited. Research with approved medicines that act on GIP or GLP-1 signals shows that weight regain can occur after treatment stops, but the amount and timing cannot simply be applied to retatrutide.

Obesity is a chronic condition, and a medicine that changes appetite and energy balance does not necessarily produce permanent biological effects after it is withdrawn. Future retatrutide studies will need to show what happens during longer treatment and after discontinuation.

The absence of a complete answer should be stated plainly rather than filled with assumptions from related medicines.

What is still unknown?

Despite the large headline results, important questions remain:

  • Whether regulators will approve retatrutide, and which groups and conditions an approval would cover
  • What safety warnings, reasons not to use it and medical checks an approved label would contain
  • How benefits and risks compare directly with current semaglutide and tirzepatide products
  • Whether it reduces heart, circulation or kidney events rather than only changing measurements linked with those risks
  • How its safety changes when people receive it for several years
  • How often rare serious side effects occur
  • What happens after long-term treatment is stopped
  • Whether findings for liver disease, joint pain and damage, or other conditions lead to approved uses
  • How results vary in groups that made up only a small part of individual trials

Some questions do not yet have reliable answers because retatrutide is still moving through the research and approval process.

What does FDA say about retatrutide compounding?

FDA states that retatrutide cannot be used in compounding under US federal law. It is not an ingredient in an FDA-approved drug. This is a US regulatory statement; it should not be extended to other jurisdictions without their own sources. Calling a product compounded or research use only does not make it an approved retatrutide medicine.

Can retatrutide be bought for personal use?

There is no approved retatrutide medicine for personal treatment as of 2 November 2026.

Websites may sell products labelled “retatrutide”, “research use only” or “not for human consumption”. Those labels do not establish that the contents match the material used in Eli Lilly and Company's trials. They also do not provide the controlled manufacturing, checks for contamination, ongoing safety monitoring or prescribing safeguards of an approved medicine.

This guide does not recommend suppliers, provide purchasing links or explain self-administration. Anyone seeking treatment for obesity, diabetes or another condition should discuss approved options with a qualified healthcare professional.

How does this guide relate to the Retatrutide storage article?

This page explains the molecule, clinical evidence, development status and safety uncertainties.

Orentra's separate Retatrutide Storage and Stability guide examines what published research can and cannot tell us about laboratory handling and stability. It is a technical reference, not an instruction for preparing or using retatrutide in people.

Keeping the subjects separate allows this page to explain the medicine without turning it into instructions for using it.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is retatrutide a GLP-1 medicine?

Partly. Retatrutide activates the GLP-1 receptor, but it also activates GIP and glucagon receptors. It is therefore described more precisely as a triple agonist.

Is retatrutide the same as Mounjaro or Zepbound?

No. Mounjaro and Zepbound contain tirzepatide, which activates GIP and GLP-1 receptors. Retatrutide activates those two receptors plus the glucagon receptor and remains investigational.

Is retatrutide the same as Ozempic or Wegovy?

No. Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist. Retatrutide is a different molecule with activity at three receptors.

How much weight did people lose in retatrutide trials?

Results differed according to the trial, the people studied, the administration level and the way researchers calculated the result. The published TRIUMPH-1 treatment-regimen analysis reported up to 25.0% average weight reduction at 80 weeks, versus 3.9% with placebo. These are group averages, not predictions for an individual.

What does LY3437943 mean?

LY3437943 is retatrutide's development code. It refers to the same investigational molecule.

Has the FDA approved retatrutide?

No. Eli Lilly and Company has announced plans to submit an application, but an application and an approval are different events.

When will retatrutide be available?

There is no guaranteed availability date. Timing depends on when an application is submitted, how regulators assess it, their final decision, manufacturing and any approved launch plans.

Is there a safe retatrutide dose?

There is no approved retatrutide dose because there is no approved retatrutide product. Trial levels were selected and monitored under detailed research plans and should not be converted into self-use instructions.

Can retatrutide be combined with semaglutide or tirzepatide?

This guide does not recommend combining medicines, sometimes called “stacking”. Retatrutide, semaglutide and tirzepatide affect some of the same hormone signals, and retatrutide is investigational. Combining them outside a properly authorised study would not recreate the evidence from trials that tested them separately.

Does retatrutide cure obesity or diabetes?

No trial has shown that it cures either condition. Trials measure changes during a defined period of treatment. Long-term outcomes and effects after withdrawal remain under study.

What the evidence supports today

Retatrutide is a closely watched investigational medicine now in late-stage research. Its three-receptor design has produced large average changes in weight and blood-sugar measures across Phase 2 and Phase 3 trials.

Retatrutide is not approved. Several Phase 3 trials are published, while other findings remain sponsor announcements. A direct semaglutide comparison has reported topline results; the separate tirzepatide comparison remains a different question. Long-term health outcomes and rare risks need further evidence.

The evidence from human trials is promising, but regulatory review has not yet taken place and important questions remain.

RESEARCH AND MEDICAL NOTICE

This guide is educational and does not provide medical advice, diagnosis, treatment, dosing, injection or purchasing instructions. Trial administration levels are reported only to explain published research. Retatrutide is investigational and has not been approved by the FDA. Treatment decisions should be made with a qualified healthcare professional using approved medicines and current prescribing information.

RESEARCH LIBRARY

Sources

Peer-reviewed researchPubMed
TRIUMPH-1Open source →
Peer-reviewed researchPubMed
TRIUMPH-2Open source →
Peer-reviewed researchPubMed
Retatrutide sleep-apnoea trialsOpen source →
Peer-reviewed researchPubMed
TRANSCEND-T2D-1Open source →
Peer-reviewed researchNew England Journal of Medicine
Jastreboff et al. Retatrutide for obesity, Phase 2 trialOpen source →
Peer-reviewed researchThe Lancet
Rosenstock et al. Retatrutide in type 2 diabetes, Phase 2 trialOpen source →
Peer-reviewed researchPubMed
Coskun et al. Discovery and preclinical characterisationOpen source →
Peer-reviewed researchPubMed
Urva et al. First-in-human studyOpen source →
Peer-reviewed researchPubMed
Retatrutide and gastric emptyingOpen source →
Trial recordsClinicalTrials.gov
TRIUMPH-1Open source →
Trial recordsClinicalTrials.gov
TRIUMPH-2Open source →
Trial recordsClinicalTrials.gov
TRIUMPH-4Open source →
Trial recordsClinicalTrials.gov
TRANSCEND-T2D-1Open source →
Trial recordsClinicalTrials.gov
Direct comparison with semaglutideOpen source →
Trial recordsClinicalTrials.gov
Cardiovascular and kidney outcomes studyOpen source →
Regulatory and clinical definitionsFDA
FDA concerns with unapproved GLP-1 drugsOpen source →
Regulatory and clinical definitionsFDA
FDA explanation of clinical-trial phasesOpen source →
Regulatory and clinical definitionsniddk.nih.gov
NIDDK explanation of the HbA1c testOpen source →
Phase 3 company announcementsEli Lilly
TRANSCEND-T2D-2, October 2026Open source →
Phase 3 company announcementsEli Lilly
TRIUMPH-1 resultsOpen source →
Phase 3 company announcementsEli Lilly
TRIUMPH-2 and TRIUMPH-3 resultsOpen source →
Phase 3 company announcementsEli Lilly
TRIUMPH-4 resultsOpen source →
Phase 3 company announcementsEli Lilly
TRANSCEND-T2D-1 resultsOpen source →

Research reviewed through 17 November 2026.